Society ＞ Together with Patients and Healthcare Professionals Solving Issues Related to Improving Access to Healthcare
Efforts to Solve Issues Related to Improving Access to Healthcare
In the Sustainable Development Goals (SDGs) adopted at the UN Summit held in September 2015, one of the goals is to "Ensure healthy lives and promote well-being for all at all ages." Under its corporate philosophy that states, "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals," the Group has contributed to society by providing treatment methods mainly using pharmaceuticals. However, there are still many intractable diseases for which a cure has yet to be found and difficult-to-cure diseases. The mission of drug discovery companies is to continuously create new drugs that meet unmet medical needs. In addition, there are many people in the world who cannot obtain the necessary pharmaceuticals and medical services, especially in developing countries, due to inadequate healthcare systems, poverty, and disasters. The Group will work to solve the issue of improving access to medicine and healthcare through its business activities and collaborative activities with various partners including NPOs, NGOs, and industrial groups.
Promotion of R&D
To improve access to medicine, it is important to continuously create innovative new drugs that meet unmet medical needs. We are actively promoting open innovation to continuously create valuable new drugs. We will also begin gene drug discovery to provide new drugs and healthcare services for the prevention and cure of intractable and rare diseases, and will play a distinctive role in addressing challenges in the global health field.
Participation in the Global Health Innovative Technology Fund
The Global Health Innovative Technology Fund (GHIT Fund), is Japan's first public-private partnership to promote the creation of innovative treatment agents for infectious diseases that affect people in developing countries, such as malaria, tuberculosis, and neglected tropical diseases. We support the GHIT Fund's objective of contributing to global health, and financially support the fund. Through the GHIT Fund, the Company provided its pharmaceutical compound library (50,000 compounds) to Medicines for Malaria Venture (MMV), a research institution that focuses on the discovery of new anti-malaria drugs. Three types of promising hit compounds that have the potential to become pharmaceutical products have been identified. In addition, we promoted joint research and from one of these compounds, we acquired two lead compounds as new anti-malaria drug candidates. In April 2019, we will move to the next phase and continue conducting research in collaboration with MMV to create candidate compounds. Malaria, along with AIDS and tuberculosis, is one of the three major infectious diseases in the world, and its eradication is a goal of the United Nations SDGs. As always, we will contribute to improving access to ethical drugs in developing countries and achieving the SDGs.
- Intractable disease initiatives Example: amyotrophic lateral sclerosis (ALS)
- Promoting open innovation (collaboration with academia, pharmaceutical companies, and GHIT Fund)
Please see “Research & Development” for details.
Creating a Stable Drug Distribution System (Supply Chain Management)
As a pharmaceutical company, Mitsubishi Tanabe Pharma is working to steadily and accurately provide high-quality pharmaceuticals, when they are needed and to the patients who need them.
Even in the event of a disaster or other unexpected situation, it's the same. To stably deliver pharmaceuticals that maintain their quality to patients, we have created a system to prevent the mixing of counterfeit pharmaceuticals and the distribution of pharmaceuticals of suspect quality including counterfeit pharmaceuticals.
For details, please see “Manufacturing and Supply Chain.”
Improving Access to Pharmaceuticals and Healthcare Services
Patents in countries where access to healthcare is difficult
Under its corporate philosophy, the Mitsubishi Tanabe Pharma Group has established a policy on intellectual property that forms the basis for providing new healthcare opportunities in order to appropriately protect and make effective use of its globally competitive intellectual property. On the other hand, in countries where serious economic problems make access to healthcare difficult, we need to consider enforcing our patents rights. The Group contributes to healthcare access in economically deprived areas around the world. Therefore, as a general rule, we do not file patent applications or enforce our patent rights in the Least Developed Countries (LDCs) stipulated by the United Nations and Low-Income Countries (LICs) specified by the World Bank.
Supporting Access to healthcare in Developing Countries by Donating to NPOs and NGOs
|Support provided||Description of initiatives||Countries targeted|
|Vaccines to children in developing countries||Since 2014, Group employees have participated in vaccine support activities for children in developing countries, which are conducted by the NPO Japan Committee, Vaccines for the World's Children (JCV). This is an international contribution activity wherein donated used books and other items are sold and that amount is donated to JCV and used to deliver vaccines to children in developing countries.||Myanmar, Laos, etc.|
|Pharmaceuticals to developing countries||The Group contributes to the health of patients in developing countries who don't have access to medical care by donating its products to overseas medical volunteer NPOs operating in Africa (Kenya).||Kenya|
|Child palliative care in developing countries||In the hope of providing palliative care services equally to all children, Mitsubishi Tanabe Pharma Indonesia donates and provides pharmaceuticals to the NGO Rachel House, a pioneer in palliative care in Indonesia. Through this activity, we help children suffering from serious illnesses in areas outside Jakarta where medical care is unavailable.||Indonesia|
Please see “Contributions to Medical Care and Welfare” for details about these initiatives.
Supporting ALS Patients with the Establishment of Searchlight Support
Radicava was approved as a treatment agent for amyotrophic lateral sclerosis (ALS) in the U.S. in May 2017. It has been marketed by Mitsubishi Tanabe Pharma America since August of that year. Searchlight Support was established to support ALS patients who have been prescribed Radicava. It supports patients by providing programs including treatment management tailored to each patient and insurance reimbursement support.